Kazia Therapeutics Ltd · NASDAQ:KZIA

Kazia Therapeutics — Investor Presentation (May 2024)

18 slides from Kazia Therapeutics's investor presentation, May 2024

  1. Slide 1: A Diversified, Clinical-Stage Oncology Drug Development Company

    A Diversified, Clinical-Stage Oncology Drug Development Company EVT801: A clinical stage, first-in-class small molecule targeting tumor (lymph)-angiogenesis Non-confidential deck May 2024 NASDAQ: KZIA | Twitter: @KaziaTx

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve substantial risks and uncertainties, not all of which may be known at the time. All state

  3. Slide 3: Targeting angiogenesis is a well-established approach in the treatment of cancer

    Targeting angiogenesis is a well-established approach in the treatment of cancer Product Company Target Indications Annual Sales (US$)* • Colorectal cancer • Lung cancer VEGF-A • Breast cancer $7 billion • Other cancers VEGFRs • Hepatocellular carcinoma PDGFRs • Renal cell carcinoma $1 billion RAF k

  4. Slide 4: Despite their proven efficacy, angiogenesis inhibitors are limited by several key challenges

    Despite their proven efficacy, angiogenesis inhibitors are limited by several key challenges Angiogenesis inhibitors work by 1 reducing the formation of new blood Tumour Hypoxia vessels around the tumour, starving it Sustained tumour hypoxia Limited of vital nutrients needed for tumour activates ada

  5. Slide 5: EVT801 is a highly selective VEGFR3 inhibitor, primarily inhibiting lymphangiogenesis

    EVT801 is a highly selective VEGFR3 inhibitor, primarily inhibiting lymphangiogenesis (formation of new lymphatic vessels) Highly selective for VEGFR3 Oral Presentation Expected to minimise off-target toxicities Administered by mouth once or twice daily Strong IP Protection Composition-of-matter to

  6. Slide 6: EVT801 selectively inhibits VEGFR3

    EVT801 selectively inhibits VEGFR3 Avastin Lucentis (bevacizumab) (ranibizumab) VEGF-B VEGF-A VEGF-D VEGF-E VEGF-C Sutent EVT801 (sunitinib) VEGFR1 VEGFR2 VEGFR3 Nexavar (sorafenib) Inlyta Cell Survival Signal Modulation Angiogenesis (axitinib) Votrient (Lymph)- Vasculogenesis angiogenesis (panzopan

  7. Slide 7: EVT801: A differentiating anti-tumour approach

    EVT801: A differentiating anti-tumour approach Inhibition of tumour escape and metastasis • Stabilisation of tumour vasculature 1 • Inhibition of (lymph)-angiogenesis • Avoidance of hypoxia decreases potential for metastatic spread Increase in anti-tumour immune activity • No impact on T-cells viabi

  8. Slide 8: Preclinical data confirms activity of EVT801 (1/2)

    Preclinical data confirms activity of EVT801 (1/2) Dramatic single-agent activity in DEN-induced Hepatocellular carcinoma model Tumour Growth Metastasis Experimental Methods Total Tumour Volume Number of Tumours in the Liver • Syngeneic mouse model • HCC chemically induced with 85% reduction 50% red

  9. Slide 9: Preclinical data confirms activity of EVT801 (2/2)

    Preclinical data confirms activity of EVT801 (2/2) Synergistic activity in combination with anti-CTLA4 mAb Tumour Volume (mm3) 500 Experimental Methods • Orthotopic tumour mouse model Vehicle EVT801 • 4T1 tumour cells inoculated in BALB/c mice 400 (mammary fat pad) anti-CTLA4 EVT801 + anti-CTLA4 • T

  10. Slide 10: Anti-tumour effects of EVT801

    Anti-tumour effects of EVT801 EVT801 preclinical data available upon request • Shows strong in vitro activity on NCI-H1703 human lung cancer tumour cell line expressing VEGFR3 • Elicits potent in vivo efficacy on tumour cells expressing VEGFR-3 • More effective than pazopanib in rhabdomyosarcoma PDX

  11. Slide 11: EVT801 is safer and has a unique mode of action compared to angiokinase inhibitors

    EVT801 is safer and has a unique mode of action compared to angiokinase inhibitors Unique mode of action: Characteristics EVT801 Angiokinase inhibitors • Tumour blood vessel normalization through avoidance of • Tumour escape due to only transient tumour Blood vessel normalization hypoxia decreases p

  12. Slide 12: EVT801 measures favorably against current anti-VEGF agents

    EVT801 measures favorably against current anti-VEGF agents Multi-VEGF Cellular in vitro IC50 (nM) Target characteristic EVT801 inhibitors Compound VEGFR2 VEGFR3 Potent small molecule VEGFR3 inhibitor 🗸 🗸 High selectivity over other VEGF receptors EVT801 241 21 and TK panel 🗸 X EVT801 metabolite…

  13. Slide 13: Unlike most mTKIs, EVT801 does not inhibit CD3+ T-cell function

    Unlike most mTKIs, EVT801 does not inhibit CD3+ T-cell function % Live Cells % Cells Compound (0 – 100uM) • Sorafenib and axitinib inhibit T-cell proliferation • Similar to Lenvatinib, EVT801 and its metabolite have no negative impact on T-cell viability and proliferation More differential data is a

  14. Slide 14: Phase 1 dose-finding trial ongoing in France – KZA 0801-101: NCT05114668

    Phase 1 dose-finding trial ongoing in France – KZA 0801-101: NCT05114668 Target population: Histologically-confirmed advanced or metastatic solid tumours, unresponsive to standard treatment, or for whom no standard treatment is available or appropriate STAGE 1 STAGE 2 Monotherapy dose escalation Bio

  15. Slide 15: Exploratory biomarkers during Phase 1 clinical trial

    Exploratory biomarkers during Phase 1 clinical trial EVT801 Biomarkers Strategy 1 3 Patient characterization based on VEGFR-3 Circulating endpoint /CAIX/CD8 expression on archival tissues biomarkers: and/or biopsies • Immunomonitoring based • VEGFR-3 protein signature by histology on CD8pos T-cells

  16. Slide 16: Study status of KZA 0801-101

    Study status of KZA 0801-101 EVT801 Clinical Study Protocol Number Study Name Study Update KZA 0801-101 A Phase 1, First in Human, Open Label Study to Stage 1 is complete - primary and secondary endpoints achieved: Assess the Safety, Tolerability, and • 32 patients included in the study with 26 pati

  17. Slide 17: Key Points

    Key Points 1 Well understood mechanism (anti-angiogenesis) with unique differentiating feature (high VEGFR3 selectivity) 2 Very strong preclinical data package, with evidence of activity in multiple tumours and favourable toxicology 3 Potential for combination use with immuno-oncology therapies 4 On

  18. Slide 18: www.kaziatherapeutics.com

    www.kaziatherapeutics.com info@kaziatherapeutics.com

Kazia Therapeutics — Investor Presentation (May 2024) on 6ix